Impact of Blood Culture Positivity Time on Clinical Management of Pediatric ICU Patients

NCT ID: NCT05507957

Last Updated: 2022-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2025-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sepsis accounts for high morbidity and mortality rates in ICU globally. Early recognition of sepsis with appropriate antimicrobial therapy is critical for the appropriate management of patients (1).

Blood culture (BC) is considered the gold standard for sepsis etiological diagnosis , with good sensitivity ,but suffering usually of delay or even failure to detect microorganisms in patients already treated with antimicrobials and failure to identify pathogens other than bacteria or yeast (2, 3).

Time-to-positivity (TTP) of blood cultures is defined as the time from the start of incubation to a positive signal. Knowledge of the distribution of blood culture TTP is of clinical benefit in the re-evaluation of patients with a clinical syndrome consistent with infection. A low probability of bacteremia when blood cultures have remained negative after 24 hours (4). Positive episodes with TTP more than or equal 24 h are commonly optimally treated infections, catheter-related infections, or infections caused by slowly growing microorganisms such as Candida or anaerobic Gram-negative bacteria. Growth of multidrug-resistant Gram-negative bacilli is exceptional beyond 24 h. In current clinical practice, bacteremia is considered unlikely if blood cultures have been negative for 48-72 hours (5, 6). Most blood culture bottles turn positive in less than 4 days, shortening the duration of incubation appears the most relevant solution in order to free additional capacity(4).

Various disinfectants, such as povidone iodine (PVI), alcohol preparations, and chlorhexidine gluconate ethanol (CHG-ALC), are used for disinfection prior to blood culture sampling. Contamination rates of cultured blood samples vary according to the disinfectant used, sampling site, definition of contamination, and skill level of individuals performing the venipuncture.(7, 8)

In this study, Investigators assessed the real life clinical impact on septic ICU patients based on time of blood culture positivity time.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aim(s) of the Research :

1. Evaluate the impact of blood culture positivity time in real -life clinical practice (patient management and reduction of ICU stay, as well as decreases in 30-days mortality.)
2. Investigates the probability of blood culture positivity after 24 hours.
3. evaluate if there was diagnostic value of TTP
4. Identify if there is difference in the blood culture contamination rate between uses of various type of disinfectant.

Sample Size Calculation: 120 septic patient in pediatric intensive care unit

Study tools:

The following will be done to all patients:

Data collection:

Clinical data (were retrieved from the medical records) :

* age and weight
* Date and time of culture collection
* pre-existing medical conditions (concomitant disease).
* Clinical parameters at presentation. The most likely source of bacteremia
* if start empirical antibiotic treatment before collection or not and its type, duration (concomitant antimicrobial therapy)
* volume of blood drawn in the bottles
* outcome data. Including change of antibiotic treatment and time to switch to directed therapy, length of ICU stay and 30-day mortality.

Microbiological data (were retrieved from the database of the Department of Medical Microbiology.) :

* date and time of bottle loading ( to know transportation time)
* date and time in which growth was first reported
* TTP(time to positivity of blood culture)
* Pathogen detected by blood culture

Blood culture sampling :

* collecting blood samples as soon as possible after the onset of clinical symptoms, ideally prior the administering antimicrobial therapy.
* Disinfection using povidone-iodine, alcohol preparation, or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients
* collect 2 sets of blood culture bottles. blood culture was obtained either at one time or over a brief time period (e.g. within 1 hour) from multiple venipuncture sites.
* Blood for culture must be collected and dispensed aseptically with great care to avoid contaminating the specimen and culture medium

Blood culture handling procedures and laboratory techniques:

* Rapid transportation to microbiology unit.
* Rapid bottle loading in bioMerieux BacT/Alert Virtuo where it was incubated for 5 days
* Direct Gram stain was performed for all positive blood culture bottles.
* Followed by subculture onto solid agar media, including blood agar, chocolate agar \& MacConkey agar and sabaroud agar (Diagnostic Media products(DMP). Then identification of microorganisms and antibiotic susceptibility by Vitek 2.
* Direct reporting method to the pediatric intensive care unit
* The presence of one of the following microorganisms in a single BC bottle or Blood Culture set was considered as contaminant: coagulase-negative staphylococci (CoNS), with the exception of S. lugdunensis, Propionibacterium spp., Bacillus spp. other than B. anthracis, Corynebacterium spp. (diphtheroids), Aerococcus-like organisms, Micrococcus spp., viridans group streptococci other than S. pneumoniae, and Neisseria spp. other than N. gonorrhoeae or N. meningitidis. These microorganisms were considered as significant when other BC bottles collected 48h before were positive with the same microorganism, after reviewing of clinical data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

direct reporting of time to positivity of blood culture to ICU to know its effect to patients managment

-Disinfection using povidone-iodine, alcohol preparation or chlorhexidine gluconate ethanol (CHG-ALC ), so that each type was used on 40 patients

Intervention Type DIAGNOSTIC_TEST

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

use different type of disinfectants (povidone iodine (PVI), alcohol preparations, and chlorhexidine gluconate ethanol (CHG-ALC)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The population of our study were patients in ICU unit in pediatric hospital of Assuit University Hospitals, that presented with clinical symptoms which may lead to a suspicion of a bloodstream infection or sepsis which is:

* Undetermined fever ( ≥ 38°C) or hypothermia ( ≤ 36°C).
* Shock, chills, rigors
* Severe local infections (meningitis, endocarditis, pneumonia, pyelonephritis, intra-abdominal suppuration etc.) Multiple episodes of bacteremia per patient were allowed if the antimicrobial therapy for the previous episode had been completed and clinical and microbiological cure had been achieved

Exclusion Criteria

-blood culture bottles that were drawn in vacation days (because of no distinct control on transportation time, which affect TTP)
Minimum Eligible Age

1 Day

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Fatma Salah EL-Dein Hosney

master of clincical patholofy

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

mohammed Z Abo krisha, professor

Role: PRINCIPAL_INVESTIGATOR

Assiut University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Assuit university

Asyut, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

fatma s elnaggar, master

Role: CONTACT

+201065074152

amal m hosni, doctora

Role: CONTACT

00201026122444

References

Explore related publications, articles, or registry entries linked to this study.

endnote

Reference Type RESULT

Related Links

Access external resources that provide additional context or updates about the study.

https://pubmed.ncbi.nlm.nih.gov/33893569/

Seasonal variations in blood culture numbers and time to positivity and potential impact of reducing incubation periods

https://pubmed.ncbi.nlm.nih.gov/27916290/

Time to positivity of blood cultures in patients with bloodstream infections: A useful prognostic tool

https://pubmed.ncbi.nlm.nih.gov/34307728/

Neither Blood Culture Positivity nor Time to Positivity Is Associated With Mortality Among Patients Presenting With Severe Manifestations of Sepsis: The FABLED Cohort Study

https://pubmed.ncbi.nlm.nih.gov/32008937/

Chlorhexidine alcohol versus povidone-iodine: The comparative study of skin disinfectants at the blood transfusion centers of Iran

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

fatma elnaggar

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Thyroid and Adrenal Disorders in ICU
NCT07245550 NOT_YET_RECRUITING